Madrigal Pharmaceuticals/$MDGL
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About Madrigal Pharmaceuticals
Madrigal Pharmaceuticals Inc is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a serious liver disease with high unmet medical need that can lead to cirrhosis, liver failure, liver cancer, need for liver transplantation and premature mortality. Its medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed thyroid hormone receptor beta agonist designed to target key underlying causes of MASH.
- Ticker
- $MDGL
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 915
- Headquarters
- West Conshohocken, United States
- Website
- www.madrigalpharma.com
MDGL Metrics
BasicAdvanced
$9.9B
-
-$16.37
-0.99
-
Price and volume
Market cap
$9.9B
Beta
-0.99
52-week high
$615.00
52-week low
$399.00
Average daily volume
282K
Financial strength
Current ratio
3.205
Quick ratio
2.756
Long term debt to equity
0.662
Total debt to equity
0.664
Interest coverage (TTM)
-10.24%
Profitability
EBITDA (TTM)
-321.098
Gross margin (TTM)
91.48%
Net profit margin (TTM)
-25.32%
Operating margin (TTM)
-25.13%
Revenue per employee (TTM)
$1,400,000
Management effectiveness
Return on assets (TTM)
-17.84%
Return on equity (TTM)
-53.31%
Valuation
Price to revenue (TTM)
7.665
Price to book
18.98
Price to tangible book (TTM)
18.98
Price to free cash flow (TTM)
-47.023
Free cash flow yield (TTM)
-2.13%
Free cash flow per share (TTM)
-9.152
Growth
Revenue change (TTM)
149.04%
Earnings per share change (TTM)
10.93%
3-year earnings per share growth (CAGR)
-4.21%
10-year earnings per share growth (CAGR)
6.63%
What the Analysts think about MDGL
Analyst ratings (Buy, Hold, Sell) for Madrigal Pharmaceuticals stock.
Analyst projections of the future price of Madrigal Pharmaceuticals stock.
Bulls say / Bears say
Rezdiffra sales rose 71% year on year to $364.3 million in the second quarter, with more than 49,000 patients on treatment. That gives Madrigal a fast-growing commercial base. (Madrigal Pharmaceuticals)
Madrigal estimates that its US pool of diagnosed F2–F3 patients under specialist care grew nearly 50% in two years, to about 460,000. Continued diagnosis and treatment uptake could support further growth. (SEC)
In the Phase 3 trial, Rezdiffra improved both MASH resolution and liver fibrosis measures versus placebo at 12 months. The results provide clinical evidence behind its commercial case. (MedLibrary)
Madrigal no longer has the MASH market to itself: Novo Nordisk’s Wegovy has an indication for MASH, and other candidates are advancing. This could limit Rezdiffra’s eventual share. (Endpoints News, Investing.com)
Operating expenses exceeded quarterly sales, and Madrigal’s net loss widened to $57.9 million. Management also said commercial contracting is pressuring net prices, which may make strong sales growth harder to convert into profit. (Madrigal Pharmaceuticals, Investing.com)
Rezdiffra’s approval remains conditional on confirmatory evidence of clinical benefit. If ongoing trials fail to verify that benefit, the drug’s regulatory status could be at risk. (Madrigal Pharmaceuticals)
Data summarised monthly by Lightyear AI. Last updated on 29 Oct 2026.
MDGL Financial Performance
Revenues and expenses
MDGL Earnings Performance
Company profitability
Upcoming events
No upcoming events
MDGL News
AllArticlesVideos
Funds containing MDGL
AllUSDEURGBP
Fund name | Fund size | $MDGL weighting |
|---|---|---|
iShares Nasdaq US Biotechnology£BTEK | $1.1B | 0.63% |
iShares Nasdaq US Biotechnology$BTEC | $1.1B | 0.63% |
iShares MSCI USA Small Cap ESG Enhanced CTB€SXRG | $3.2B | 0.11% |
iShares MSCI USA Small Cap CTB Enhanced ESG£CUS1 | $3.2B | 0.11% |
Xtrackers MSCI World Small Cap$XSWC | $183M | 0.06% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.